Changes to inhaled corticosteroid dose when initiating combination inhaler therapy in long-acting β agonist-naive patients with asthma : a retrospective database analysis by Covvey, Jordan R et al.
Strathprints Institutional Repository
Covvey, Jordan R and Johnston, Blair F and Wood, Fraser and Boyter, 
Anne C (2014) Changes to inhaled corticosteroid dose when initiating 
combination inhaler therapy in long-acting β agonist-naive patients with 
asthma : a retrospective database analysis. Thorax, 69 (11). 1056 - 1058. 
ISSN 0040-6376 , http://dx.doi.org/10.1136/thoraxjnl-2013-204944
This version is available at http://strathprints.strath.ac.uk/47199/
Strathprints is  designed  to  allow  users  to  access  the  research  output  of  the  University  of 
Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights 
for the papers on this site are retained by the individual authors and/or other copyright owners. 
Please check the manuscript for details of any other licences that may have been applied. You 
may  not  engage  in  further  distribution  of  the  material  for  any  profitmaking  activities  or  any 
commercial gain. You may freely distribute both the url (http://strathprints.strath.ac.uk/) and the 
content of this paper for research or private study, educational, or not-for-profit purposes without 
prior permission or charge. 
Any  correspondence  concerning  this  service  should  be  sent  to  Strathprints  administrator: 
strathprints@strath.ac.uk
Changes to inhaled corticosteroid dose when initiating combination inhaler 
therapy in long-acting beta agonist naïve patients with asthma: a retrospective 
database analysis 
 
Jordan R Covvey Ph.D. Student1, Blair F Johnston Senior Lecturer1, Fraser Wood 
Consultant Respiratory Physician2, Anne C Boyter Senior Lecturer1 
 
1Strathclyde Institute of Pharmacy and Biomedical Sciences, University of 
Strathclyde, 161 Cathedral St, Glasgow G4 0RE, United Kingdom; 2Forth Valley 
Royal Hospital, Stirling Rd, Larbert FK5 4WR, United Kingdom 
 
Correspondence to: A Boyter anne.boyter@strath.ac.uk 
Tel: +44 (0)141 548 4594, Fax: +44 (0)141 552 2562 
 
The Corresponding Author has the right to grant on behalf of all authors and does 
grant on behalf of all authors, a worldwide licence to the Publishers and its licensees 
in perpetuity, in all forms, formats and media (whether known now or created in the 
future), to i) publish, reproduce, distribute, display and store the Contribution, ii) 
translate the Contribution into other languages, create adaptations, reprints, include 
within collections and create summaries, extracts and/or, abstracts of the 
Contribution and convert or allow conversion into any format including without 
limitation audio, iii) create any other derivative work(s) based in whole or part on the 
on the Contribution, iv) to exploit all subsidiary rights to exploit all subsidiary rights 
that currently exist or as may exist in the future in the Contribution, v) the inclusion of 
electronic links from the Contribution to third party material where-ever it may be 
located; and, vi) licence any third party to do any or all of the above. 
 
Keywords/phrases: Retrospective study, asthma, corticosteroid, beta agonist, 
adrenergic 
 
Word count: 1528 
 
Abstract: 
 
Retrospective prescribing data were obtained from 46 general practice surgeries in 
NHS Scotland. Patients with asthma who were naïve to previous LABA therapy and 
initiated combination inhaler therapy in 2008-2009 were classified according to the 
ICS dose in their combination inhaler compared to the highest dose of ICS they 
received before initiation. Among the 685 patients (541 [79.0%] who had been 
prescribed an ICS previously), those originally on low-, medium- or high-dose ICS 
were changed to high-dose combination therapy in 122/250 (48.8%), 94/151 (62.3%) 
or 85/113 (75.2%) cases in each ICS dose category, respectively. These results 
suggest that evaluation of appropriate high-dose ICS prescribing in general practice 
is needed. 
 
Main text: 
 
INTRODUCTION: 
 
Management of chronic asthma in the United Kingdom (UK) is guided by a step-wise 
approach recommended by the British Thoracic Society and Scottish Intercollegiate 
Guideline Network (BTS/SIGN) guideline.[1] Combination therapy with an inhaled 
corticosteroid (ICS) and long-acting beta agonist (LABA) is the preferred treatment at 
step 3, when the use of an ICS alone is insufficient for the control of persistent 
asthma, which is defined by the presence of symptoms, their effect oQWKHSDWLHQW¶V
quality of life, and the future risk of adverse events such as exacerbation.[1] 
Previously, escalation of ICS dose was advocated to achieve optimal control, 
however, major international guidelines now agree on the therapeutic benefits of 
adding LABA therapy to ICS therapy. 
 
The appropriate use of combination therapy has also been questioned. Breton, et al. 
described the prescribing of combination therapy against the current Canadian 
asthma guidelines and found that only 40% of patients prescribed combination 
therapy had received a prescription for an ICS in the preceding year.[2]  However, no 
analyses to our knowledge have described ICS dose transitions on initiation of 
combination therapy in patients in general practice.  The aim of this study was to 
describe dose changes during the transition from ICS to newly initiated combination 
inhaler therapy in patients with asthma. 
 
METHODS:  
 
A retrospective database analysis was conducted in 46 practices (~80% coverage) in 
the Forth Valley Health Board of National Health Service (NHS) Scotland, which 
serves nearly 300,000 patients in a representative area. Patients were included if 
they: (1) had physician-diagnosed asthma, (2) had their first prescription for a 
combination inhaler (fluticasone/salmeterol or budesonide/formoterol) between 1 
January 2008 and 31 December 2009, (3) were naïve to LABA therapy in the year 
before initiation of combination inhaler therapy. The date of the first prescription for 
combination inhaler was considered the index date for each patient.  
 Doses of the ICS component in both single-agent and combination inhalers were 
obtained from the prescription posology and standardised to beclometasone 
dipropionate (BDP) according to the BTS/SIGN guideline.[1] For patients >12 years 
of age, low-dose ICS was defined as 400 micrograms daily, medium-dose ICS as 
>400 micrograms daily and 800 micrograms daily and high-dose as ICS >800 
micrograms daily: for patients 12 years old, the dose cut-offs were halved.[1] 
Patients were assessed according to highest ICS dose they received in the year 
before the index date and the first dose of ICS in the combination therapy inhaler 
they received on the index date. Sensitivity analyses excluding patients with co-
morbid COPD and looking specifically at children were also performed. The use of 
SABA and OCS in the year before the index date were quantified as markers of 
asthma symptoms and exacerbations, respectively.  
 
RESULTS:  
 
685 patients initiated combination inhaler therapy during the study period. The 
majority of patients were women (403; 58.8%) with a median age of 47 years 
(interquartile range: 32-62 years); 89 (13.0%) patients were concurrently listed on 
practice COPD registers. 541 (79.0%) patients had been prescribed an ICS inhaler 
in the year before the index date. BDP was the most widely prescribed ICS among 
patients before the index date (294; 54.1%), and fluticasone/salmeterol was the most 
common combination inhaler therapy choice (497; 72.6%). 
 
The mean standardised dose of ICS before the index date was 677 micrograms 
compared to 1043 micrograms on initiation of combination inhaler therapy, resulting 
in a mean increase in dose of 354 micrograms (95% confidence interval [CI]: 302 to 
407 micrograms, p<0.001). Patients originally on low- or medium-dose ICS had 
mean dose increases of 550 micrograms (95% CI: 483 to 618 micrograms) or 275 
micrograms (95% CI: 186 to 363 micrograms), respectively (both p<0.001); patients 
originally on high-dose ICS had similar doses pre- and post-index (mean difference: 
21 micrograms, 95% CI: -97 to 139 micrograms, p=0.723). 
 
When patients were classified according to ICS dose categories, patients on low-, 
medium- and high-dose ICS before the index date were changed to high-dose 
combination inhalers in 122/250 (48.8% of ICS category), 94/151 (62.3%) and 
85/113 (75.2%) patients, respectively (Figure 1). Patients with no recorded 
prescribing of ICS pre-index were changed to high-dose combination inhalers in 
81/144 cases (56.3%). Fifty-two patients (10.3% of those with pre-index ICS) were 
transitioned to a lower dose combination inhaler than their ICS dose pre-index. A 
small number (27, 3.9% of total) of patients had unclear prescription instructions and 
were excluded.  Excluding the 129 patients with co-morbid COPD resulted in no 
significant changes in the overall classification, with an overall mean dose increase 
of 463 micrograms (95% CI: 406 to 520 micrograms), and high-dose combination 
inhalers remaining the post-index therapy choice in 321/596 patients (53.9%; 
comparison with the original cohort: p=0.195). Forty-four children were included in 
the analysis, with the majority (27; 61.4%) changing from low-dose ICS to low-dose 
combination therapy, and only 9 (20.5%) receiving high-dose combination therapy.  
 
Overall, 649 (94.7%) and 199 (29.1%) patients had received at least one prescription 
for SABA or OCS in the previous year, respectively. The number of SABA inhalers 
prescribed was similar albeit variable regardless of baseline ICS dose, with a median 
of 6 inhalers/year (IQR: 2-12 inhalers/year; p=0.145 for comparison among ICS 
categories). The number of OCS courses was also similar with a median of 2 
prescriptions/year (IQR: 1-3 prescriptions/year; p=0.306).  
 
DISCUSSION: 
 
This analysis demonstrates significant use of high-dose combination therapy among 
patients with asthma treated in GP surgeries. Widespread use of high-dose ICS in 
the UK has been noted previously. Thomas et al. found that within a prescribing 
analysis of over 22,000 adults/adolescents with asthma, 27% of patients received 
high-dose ICS, and 83.6% of them had no record of a trial of add-on therapy with a 
LABA or other controller therapy.[3] The present analysis found that over three-
quarters of patients received ICS therapy before starting therapy with a combination 
inhaler, suggestive of better concordance with guideline recommendations. 
However, upon addition of a LABA to the therapy regimen, there was a widespread 
pattern of simultaneous ICS dose escalation, with patients advancing directly to high-
dose combination therapy, largely irrespective of their baseline ICS dose. This 
suggests not only questionable use of high-dose ICS, but also failure to follow 
guideline recommendations. 
 
The dose-response relationship of ICS has been the subject of much research, 
although high quality evidence indicates that the therapeutic benefits of ICS are seen 
at doses of 200-1000 mcg BDP-equivalent daily.[4-5] Above this threshold, adverse 
effects of ICS such as HPA-axis suppression, osteoporosis and skin bruising are 
more common. Accordingly, the wide utilisation of high-dose ICS is likely to produce 
a poor return on investment, with an increased risk of local and systemic adverse 
effects traded for little gain in asthma control. Although as a database analysis, we 
were unable to determine the clinical reasoning underlying ICS dose changes, the 
patterns noted in this study should prompt further investigation into the 
appropriateness of high-dose ICS prescribing in UK general practice. 
 
Fluticasone/salmeterol was most commonly used high-dose combination therapy in 
this analysis, but the reasons behind this are unclear. Fluticasone may be 
preferentially chosen for treatment due to its potency and ease of dosing regimen to 
achieve higher doses. A post hoc analysis found that of the 488 patients prescribed 
high-dose combination therapy, ZHUHSUHVFULEHGGRVHVPFJGDLO\
³YHU\KLJK-GRVH,&6´DQGDOOEXWRIWKHVHSDWLHQWVUHFHLYHG
fluticasone/salmeterol. However, we also acknowledge that this prescribing may be 
inadvertent, and that a lack of awareness of potency differences between different 
ICS preparations may lead to the product being prescribed at twice the intended 
dose of budesonide/formoterol. Another contributing factor may be the licensing of 
high-dose combination therapy for the treatment of COPD. The analysis included 
patients with co-morbid COPD in the analysis, as this group of patients is often 
excluded from randomised controlled trials, despite constituting 5-20% of the asthma 
population. While it would be plausible that the inclusion of this patient group would 
inflate the use of high-dose combination therapy, the results of our sensitivity 
analysis showed no differences from the full cohort. However, clinicians may feel 
more comfortable prescribing larger doses of ICS for asthma than previously due to 
widespread use of high-dose ICS in COPD, and may alter their prescribing practices 
for patients with asthma. 
 
There was no discernible pattern of SABA/OCS prescribing among ICS dose 
categories, suggesting that patient symptoms and/or exacerbations were not primary 
motivators for dose increases during the initiation of combination inhaler therapy in 
this analysis. While symptoms and/or exacerbations may push a clinician to escalate 
therapy rapidly, changing a patient from no ICS therapy to high-dose combination 
therapy remains concerning and there is little evidence to support this approach. Our 
analysis did uncover some ICS dose step-down, albeit with the concurrent addition 
of a LABA (medium-dose ICS changed to low-dose combination inhaler). Although 
this was only seen in a small number of patients, it may provide some reassurance 
to the use of increasing doses of ICS and combination therapy. 
 
High-dose combination inhalers were prescribed frequently in this UK cohort with 
asthma, even without a history of ICS treatment. Evaluation of the appropriateness 
of high-dose prescribing in general practice is needed and educational efforts should 
focus on the dose-response relationship of ICS and the risk of adverse effects when 
using high-dose ICS. 
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